Literature DB >> 9427803

The prognostic significance of epidermal growth factor receptor expression in squamous cell carcinomas of the oesophagus.

M Torzewski1, M Sarbia, P Verreet, F Bittinger, P Dutkowski, H Heep, R Willers, H E Gabbert.   

Abstract

EGFR expression in 150 potentially curative resected squamous cell carcinomas of the oesophagus was analyzed immunohistochemically and correlated with survival. Altogether, 124 of 150 (82.7%) tumours expressed different levels of EGFR. The percentage of tumour cells expressing EGFR varied greatly between the different tumours (median: 70%). 62 (50.0%) tumours showed weak and intense staining, respectively. Regarding the staining pattern 19 (15.3%) tumours showed exclusively membraneous immunoreactivity, 27 (21.8%) an exclusively cytoplasmic immunoreactivity and 78 (62.9%) a mixed staining pattern. No significant correlation however could be found between EGFR expression and various clinicopathologic parameters such as pT category, pN category, tumour size, histologic grade and blood vessel invasion. In univariate survival analysis, no correlation between EGFR expression and postoperative survival time was observed. In a forward multivariate Cox regression analysis only the parameters lymphatic-vessel invasion (p = 0.001), pT category (p = 0.0034) and pN category (p = 0.0256), but not the EGFR expression, could be verified as independent prognostic variables. In conclusion, the evaluation of the EGFR expression does not provide prognostic information for patients who underwent potentially curative resection for SCC of the oesophagus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9427803

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma.

Authors:  Patrapim Sunpaweravong; Somkiat Sunpaweravong; Puttisak Puttawibul; Winyou Mitarnun; Chan Zeng; Anna E Barón; Wilbur Franklin; Sherif Said; Marileila Varella-Garcia
Journal:  J Cancer Res Clin Oncol       Date:  2004-10-19       Impact factor: 4.553

2.  CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.

Authors:  Peter C Enzinger; Barbara Ann Burtness; Donna Niedzwiecki; Xing Ye; Kathe Douglas; David H Ilson; Victoria Meucci Villaflor; Steven J Cohen; Robert J Mayer; Alan Venook; Al Bowen Benson; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2016-07-05       Impact factor: 44.544

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.